Protein Kinase C as a Therapeutic Target

The document reviewed the potential of Protein Kinase C (PKC) as a therapeutic target in cancer treatment, emphasizing its role in cellular processes like proliferation, differentiation, and apoptosis. It discussed various PKC isoforms and their involvement in cancers such as skin, colon, prostate, ovarian, breast, endometrial, and lung cancers. The review highlighted the challenges in developing PKC inhibitors due to the complexity of the enzyme family and the need for specificity to avoid off-target effects. Clinical trials with PKC inhibitors like enzastaurin showed promise, particularly in glioblastoma and non-Hodgkin's lymphoma, but the complexity of PKC pathways and resistance emergence posed challenges. Overall, while PKC was a promising target, further research was necessary to develop effective inhibitors.